Healthcare Sep 13, 2022 05:30 PM (GMT+8)
Nuwacell(Chinese:中盛溯源) completes hundreds of millions of CNY in a Series A financing round, which was jointly led by China Merchants Health (Chinese: 招商健康) and Legend Capital (Chinese: 君联资本) with participation from GF XINDE INVESTMENT (Chinese:广发信德). The financing will support the company in building a research and development platform and advancing its cellular drug pipeline.
Established in 2016, Nuwacell focuses on applying gene technology and stem cell technology to new drug research and development and biological drug production. The company focuses on the production and clinical transformation of iPSC-derived cell therapy products, and has systematically established a patent portfolio around the application of iPSC technology.